Dyne Therapeutics annual operating expenses
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Operating Expenses Growth & History (DYN)
Dyne Therapeutics's operating expenses was $468.2M for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $468.2M | $124.3M | +36.15% |
| 2024 | 2024-12-31 | $343.9M | $101.7M | +42.01% |
| 2023 | 2023-12-31 | $242.2M | $71.2M | +41.65% |
| 2022 | 2022-12-31 | $171.0M | $20.9M | +13.96% |
| 2021 | 2021-12-31 | $150.0M | $91.4M | +155.81% |
| 2020 | 2020-12-31 | $58.6M | $44.8M | +324.18% |
| 2019 | 2019-12-31 | $13.8M | — | — |
Dyne Therapeutics quarterly operating expenses
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $181.7M | $65.9M | +56.89% |
| Q1 2026 | 2026-03-31 | $125.3M | $2.9M | +2.37% |
| Q4 2025 | 2025-12-31 | $116.1M | $19.0M | +19.59% |
| Q3 2025 | 2025-09-30 | $113.9M | $8.2M | +7.79% |
| Q2 2025 | 2025-06-30 | $115.8M | $43.8M | +60.91% |
| Q1 2025 | 2025-03-31 | $122.4M | $53.2M | +76.95% |
| Q4 2024 | 2024-12-31 | $97.1M | $29.4M | +43.46% |
| Q3 2024 | 2024-09-30 | $105.7M | $43.4M | +69.67% |
| Q2 2024 | 2024-06-30 | $72.0M | $5.2M | +7.83% |
| Q1 2024 | 2024-03-31 | $69.2M | $23.7M | +52.11% |
| Q4 2023 | 2023-12-31 | $67.7M | $27.5M | +68.61% |
| Q3 2023 | 2023-09-30 | $62.3M | $20.0M | +47.29% |
| Q2 2023 | 2023-06-30 | $66.7M | $14.0M | +26.50% |
| Q1 2023 | 2023-03-31 | $45.5M | $9.7M | +27.05% |
| Q4 2022 | 2022-12-31 | $40.1M | −$11.8M | −22.74% |
| Q3 2022 | 2022-09-30 | $42.3M | −$487,000 | −1.14% |
| Q2 2022 | 2022-06-30 | $52.8M | $22.6M | +74.89% |
| Q1 2022 | 2022-03-31 | $35.8M | $10.6M | +42.37% |
| Q4 2021 | 2021-12-31 | $52.0M | $23.4M | +81.68% |
| Q3 2021 | 2021-09-30 | $42.8M | $29.2M | +216.32% |
| Q2 2021 | 2021-06-30 | $30.2M | $21.5M | +247.72% |
| Q1 2021 | 2021-03-31 | $25.1M | $17.3M | +220.06% |
| Q4 2020 | 2020-12-31 | $28.6M | — | — |
| Q3 2020 | 2020-09-30 | $13.5M | $9.9M | +272.55% |
| Q2 2020 | 2020-06-30 | $8.7M | — | — |
| Q1 2020 | 2020-03-31 | $7.9M | — | — |
| Q3 2019 | 2019-09-30 | $3.6M | — | — |
Dyne Therapeutics operating expenses trends
Over the last five fiscal years, Dyne Therapeutics's operating expenses increased from $58.6M to $468.2M, a change of $409.5M. The latest reported quarter, Q2 2026, shows $181.7M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...